Multiply Labs & AstraZeneca Collaborate To Automate Cell Therapy Manufacturing

Multiply Labs & AstraZeneca Collaborate To Automate Cell Therapy Manufacturing

Multiply Labs and AstraZeneca are collaborating to scale cell therapy manufacturing, a complex but promising medicine, through the use of GMP-ready robotic biomanufacturing technology. This partnership aims to increase manufacturing efficiency and make these advanced therapies more widely available.

Multiply Labs Announces New Collaboration to Automate Cell Therapy Manufacturing with Robotics

Open the article to view the coverage from The AI Journal

Multiply Labs partners with AstraZeneca to automate cell therapy manufacturing

Multiply Labs said its modular approach to cell therapy automation reduces manufacturing bottlenecks. | Source: Multiply Labs Multiply Labs Inc. today announced an agreement with AstraZeneca to evaluate the potential for applying good manufacturing practice, or GMP-ready, robotic systems to commercial-scale cell therapy manufacturing. The collaboration will focus on automation of industry-standard instruments used in cell therapy production usin…